drugset
drugset / Trial / NCT05064436

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

NCT05064436 ↗

Phase 1 Terminated 10 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to evaluate the safety, tolerability, kinetics, biodistribution and central nervous system signal of 11C-BMS-986196 after intravenous (IV) administration in healthy participants and after repeat IV administration in participants with multiple sclerosis.

Timeline

Start
2021-12-10
Primary completion
2023-12-18
Completion
2023-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986196 Unknown — Intravenous

Indications

multiple sclerosis